Viewing Study NCT04607668


Ignite Creation Date: 2025-12-24 @ 6:27 PM
Ignite Modification Date: 2025-12-31 @ 7:18 AM
Study NCT ID: NCT04607668
Status: TERMINATED
Last Update Posted: 2024-11-26
First Post: 2020-10-20
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
Sponsor: G1 Therapeutics, Inc.
Organization: